Crowdonomics
All companies
Love Sun Body logo

Love Sun Body

Operating

Love Sun Body LLC

Healthcare · West Orange, NJ · Founded 2012

Innovator of the First 100% Cosmos Natural Sunscreens & Application Technology

Post-money valuation ⓘ
$29.9M
As of Apr 2024 · from Reg CF Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$394,933
Across 3 rounds since 2020
Latest share price
$1.15
Reg CF · Preferred Stock · Mar 2024 offering price

Financials

FY2018–FY2022 · from SEC filings · hover any figure for its source
$70K
−$789K
2018
$166K
−$812K
2019
$135K
−$673K
2020
$70K
−$789K
2021
$166K
−$812K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019 reviewed
FY2020 audited
FY2021 reviewed
FY2022 reviewed
Income statement
Revenue
$70,145
$165,785
$134,961
$70,145
$165,785
Cost of goods sold
$112,307
$308,165
$54,956
$112,307
$308,165
Gross margin
-60%
-86%
59%
-60%
-86%
Net income
-$789,160
-$811,744
-$673,408
-$789,160
-$811,744
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$431,026
$202,736
$94,220
$431,026
$202,736
Accounts receivable
$2,878
$2,155
$0
$2,878
$2,155
Total assets
$608,889
$396,915
$416,397
$608,889
$396,915
Short-term debt
$48,734
$409,970
$452,481
$48,734
$409,970
Long-term debt
$0
$0
$0
$0
$0
Total liabilities
$48,734
$409,970
$452,481
$48,734
$409,970
Other
Headcount
—
5
5
—
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$21.4M
pre-money
$31.3M
pre-money
$29.9M
pre-money
Reg CF · Common · Sep 2020
Reg CF · Common · Jul 2021
Reg CF · Preferred · Mar 2024

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$1.15$0.575$0.78
Sep 2020Mar 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Raised $2.4K / $618KPost-money $29.9M
Raised $140.3K / $2MInvestors 70Post-money $31.4M
Raised $252.3K / $1.1MInvestors 103Post-money $21.6M

Team

5 people
Dr. Terry Zickerman
CEO

Dr. Terry Zickerman is the CEO and Founder of Love Sun Body. Global leader for expertise in natural sunscreen formulation and research of transdermal effects of sunscreen filters and synthetic ingredients. Love Sun Body offers consumers revolutionary natural mineral sunscreens; the first and only sunscreens in the United States that have been certified by Ecocert COSMOS Natural, that meet both the regulatory requirements of the FDA OTC Monograph System and the European Commission’s recommendation on UVA protection. Love Sun Body was conceived as a green company and has made an enduring commitment to environmental principles in its business operations. The company is a leader in environmentally friendly or green activities to ensure that all processes, products, packaging, recycling and manufacturing activities adequately address current environmental concerns while maintaining a profit. It is committed to socially responsible investments (SRI) that focus on conservation of natural resources, manufacturing, implementation of clean air and environmentally conscious business practices. At Love Sun Body, we seek to leverage our reach, scale and expertise to effect real change in sustainability issues. Our green activities and initiatives include recycling, manufacturing, socially responsible investments (SRI) that focus on conservation of natural resources, manufacturing, implementation of clean air, and other environmentally conscious business practices. We believe there is a strong connection between the health of our clients and the health of our business, our workforce, and the planet and each of these impact one another. At Love Sun Body, we are united by our sustainability strategy that is built around pillars that put health and a green initiative at the heart of our work, "Safe for your body and the planet".

Brian Gerald Brazzo
MD
Dr. Brian Brazzo
Board Member

Dr. Brazzo is a board-certified ophthalmologist and a fellowship-trained plastic surgeon. His practice is devoted to the most advanced techniques in ophthalmic plastic surgery. He is a graduate of the Harvard Medical School and University of Pennsylvania. He completed a transitional residency in medicine and surgery at Thomas Jefferson University in Philadelphia. Dr. Brazzo then completed a residency in ophthalmology at the Manhattan Eye, Ear & Throat Hospital in New York. He spent an additional three years training in ophthalmic and facial plastic surgery under some of the most prominent surgeons in the country. He completed his thesis and gained the highest standing in the American Society of Ophthalmic Plastic and Reconstructive Surgery. Dr. Brazzo is currently an attending surgeon at the New York Eye and Ear Infirmary and the New York Presbyterian Hospital, as well as a consultant at Weill Cornell Medical College. Dr. Brazzo is active in ophthalmic research and has edited six medical textbooks. He is a featured lecturer and author of numerous articles and papers. He is recognized as one of the most experienced cosmetic and oculoplastic surgeons New York has to offer. Clinically, he specialized in the care of patients with cosmetic and reconstructive concerns of the area around the eyes, including the eyelids, orbit and lacrimal systems. He has performed cosmetic surgery on some of the most famous names in the entertainment industry. A revered oculoplastic surgeon who patients trust with all their ophthalmic plastic surgery needs, Dr. Brazzo skillfully performs blepharoplasty (eyelid surgery), ptosis treatment and various non- surgical cosmetic procedures such as Botox and facial fillers in New York City. He also helps his Manhattan Latisse patients grow thicker, longer eyelashes.

Kevin Gallagher
Board Member

Kevin Gallagher was the President of Croda’s Global Personal Care & Actives business. In this capacity, he had P&L responsibility for Croda’s Global Personal Care & Actives businesses around the world. In addition, he was President Croda Inc. He also served as a member of the Executive Committee of Croda International Plc. Throughout his 37-year career at Croda, Mr. Gallagher has held diverse roles in R&D and Quality Management, Sales and Marketing. He has been active within the Chemical industry and has had the honor of serving on the American Cleaning Institute (ACI) Board of Directors (also Executive Committee and Chair of the Nominations Committee), the Personal Care Product Council (PCPC) Board of Directors, the Newark College of Engineering (NJIT) Advisory Board and the Rutgers University Chemistry and Chemical Biology Advisory Board.

Steve Liaci
Board Member

Steve Liaci has 25 years of sales and management experience in the medical equipment industry. Steve graduated Gettysburg College in 1992 with a degree in Spanish/Latin American Studies and worked as a sales representative at Garden State Business Machines selling Sharp electronics products from 1992-1993. After Garden State Business Machines, Steve worked at Abbott Laboratories as a medical sales representative from 1994 to 1996 selling antibiotic and antihypertensive medications. In 1997 Steve began selling wheelchairs/accessories and hospital beds for ROHO, a division of Permobil, where he was employed as a Divisional District Manager of medical equipment until June 1, 2016. In 2018, Steve joined Invacare in 2016 as a Rehab Sales Specialist. For enjoyment, Steve has been training on piano for the last 8 years and enjoys performing for select groups.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 2 of 6 annual reports (FY2020–FY2025)

103 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form CJan 16, 20240001670254-24-000034
    EDGAR
  • Form C-ARJan 16, 20240001670254-24-000033
    EDGAR
  • Form C-UOct 4, 20220001665160-22-002597
    EDGAR
  • Form C-UJan 5, 20220001665160-22-000029
    EDGAR
  • Form C/ASep 21, 20210001665160-21-001677
    EDGAR
  • Form C/AAug 13, 20210001665160-21-001465
    EDGAR
  • Form C/AAug 4, 20210001665160-21-001400
    EDGAR
  • Form C/AAug 4, 20210001665160-21-001402
    EDGAR
Source: ManualCIK 0001820463DEShare price $1.15

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.